Spots Global Cancer Trial Database for stage iv bladder cancer
Every month we try and update this database with for stage iv bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | NCT00066352 | Bladder Cancer Transitional Ce... | bortezomib | 18 Years - | University Health Network, Toronto | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | NCT01846520 | Healthy Subject Localized Trans... Metastatic Tran... Psychosocial Ef... Recurrent Bladd... Recurrent Cervi... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Recurrent Trans... Recurrent Ureth... Recurrent Uteri... Regional Transi... Stage II Bladde... Stage II Renal ... Stage II Urethr... Stage IIA Cervi... Stage IIA Colon... Stage IIA Gastr... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Pancr... Stage IIA Recta... Stage IIA Uteri... Stage IIB Cervi... Stage IIB Colon... Stage IIB Gastr... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Pancr... Stage IIB Recta... Stage IIB Uteri... Stage IIC Colon... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Recta... Stage III Bladd... Stage III Pancr... Stage III Renal... Stage III Ureth... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Gast... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Gast... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Uter... Stage IV Bladde... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Urethr... Stage IVA Cervi... Stage IVA Colon... Stage IVA Recta... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Colon... Stage IVB Recta... Stage IVB Uteri... Ureter Cancer Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung... | educational int... telephone-based... quality-of-life... questionnaire a... | 18 Years - | City of Hope Medical Center | |
| Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | NCT00003342 | Bladder Cancer Transitional Ce... | filgrastim carboplatin doxorubicin hyd... gemcitabine hyd... paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | NCT00082719 | Bladder Cancer Urethral Cancer | Recombinant Int... | - | M.D. Anderson Cancer Center | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder | NCT01124682 | Bladder Cancer | diagnostic cyst... diffusion-weigh... implanted fiduc... quality-of-life... 3-dimensional c... image-guided ra... selective exter... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | NCT00792025 | Bladder Cancer Transitional Ce... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | NCT00627432 | Bladder Cancer | gemcitabine hyd... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | NCT01191892 | Bladder Cancer Transitional Ce... Ureter Cancer Urethral Cancer | carboplatin gemcitabine hyd... vandetanib Placebo | 18 Years - 120 Years | Cardiff University | |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | NCT00478361 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | Gemcitabine hyd... Paclitaxel Doxorubicin hyd... Pegfilgrastim | - | M.D. Anderson Cancer Center | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | NCT00041171 | Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp... | Hypericum perfo... docetaxel placebo | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00004095 | Bladder Cancer Breast Cancer Colorectal Canc... Kidney Cancer Lung Cancer Pancreatic Canc... | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Northwestern University | |
| Docetaxel in Treating Patients With Solid Tumors | NCT00003565 | Bladder Cancer Breast Cancer Head and Neck C... Lung Cancer Unspecified Adu... | docetaxel | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | NCT00003376 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium | NCT00028756 | Stage III Bladd... Stage IV Bladde... Transitional Ce... | doxorubicin hyd... gemcitabine hyd... vinblastine sul... methotrexate cisplatin filgrastim | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | NCT04267575 | Recurrent Malig... Stage IV Breast... Stage IV Prosta... Stage IV Pancre... Stage IV Non-sm... Stage IV Ovaria... Stage IV Fallop... Stage IV Colon ... Stage IV Colore... Stage IV Liver ... Stage IV Renal ... Stage IV Rectal... Stage IV Lung C... Stage IV Small ... Stage IV Gastri... Stage IV Bladde... | Canady Helios C... | 18 Years - | Jerome Canady Research Institute for Advanced Biological & Technological Sciences | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00004095 | Bladder Cancer Breast Cancer Colorectal Canc... Kidney Cancer Lung Cancer Pancreatic Canc... | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Northwestern University | |
| Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | NCT00021099 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder | NCT00084578 | Bladder Cancer | celecoxib rosiglitazone m... conventional su... neoadjuvant the... | 18 Years - | Fox Chase Cancer Center | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | NCT00089128 | Bladder Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors | NCT00019435 | Bladder Cancer Breast Cancer Colorectal Canc... Esophageal Canc... Gastric Cancer Lung Cancer Pancreatic Canc... | LMB-9 immunotox... | 18 Years - | National Cancer Institute (NCI) | |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer | NCT00003167 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Transitional Ce... | Ad5CMV-p53 gene | 18 Years - | National Cancer Institute (NCI) | |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | NCT04267575 | Recurrent Malig... Stage IV Breast... Stage IV Prosta... Stage IV Pancre... Stage IV Non-sm... Stage IV Ovaria... Stage IV Fallop... Stage IV Colon ... Stage IV Colore... Stage IV Liver ... Stage IV Renal ... Stage IV Rectal... Stage IV Lung C... Stage IV Small ... Stage IV Gastri... Stage IV Bladde... | Canady Helios C... | 18 Years - | Jerome Canady Research Institute for Advanced Biological & Technological Sciences | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| 3 Tesla MRI in Patients With Bladder Cancer | NCT00938145 | Bladder Cancer | Specimen Ultra-... chemotherapy Cystectomy and ... | 18 Years - | University of Cincinnati | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00083213 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | NCT00072137 | Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom... | - | National Cancer Institute (NCI) | |
| Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer | NCT00054626 | Bladder Cancer | cisplatin gemcitabine hyd... adjuvant therap... | 18 Years - 74 Years | National Cancer Institute (NCI) | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| Adjuvant Radiation for High Risk Bladder Cancer | NCT01954173 | Bladder Cancer Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... | 3D conformal ra... | 18 Years - | Emory University | |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | NCT00082706 | Bladder Cancer Urethral Cancer Urachal Cancer | 5-Fluorouracil ... Leucovorin Cisplatin Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | NCT00005858 | Bladder Cancer Breast Cancer Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | LMB-9 immunotox... | 18 Years - | University of Maryland, Baltimore | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | NCT01938573 | Recurrent Bladd... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Cisplatin Gemcitabine Hyd... Sirolimus Cystectomy | 18 Years - | University of Washington | |
| Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | NCT00623064 | Bladder Cancer Transitional Ce... | cisplatin gemcitabine hyd... lapatinib ditos... pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | NCT00002949 | Bladder Cancer Cervical Cancer Endometrial Can... Vaginal Cancer | paclitaxel vinorelbine tar... radiation thera... | 18 Years - | University of Chicago | |
| Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer | NCT02316548 | Stage III Bladd... Stage IV Bladde... | Intensity-Modul... | 18 Years - | NRG Oncology | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | NCT00004223 | Bladder Cancer Transitional Ce... Urethral Cancer | docetaxel gemcitabine hyd... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | NCT00112671 | Metastatic Tran... Recurrent Bladd... Recurrent Trans... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer | NCT00028860 | Bladder Cancer Transitional Ce... | filgrastim carboplatin gemcitabine hyd... ifosfamide paclitaxel adjuvant therap... | - | National Cancer Institute (NCI) | |
| SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00006351 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... lonafarnib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | NCT00053209 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | NCT03229278 | Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So... | Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | NCT00072137 | Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom... | - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | NCT00397488 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | NCT00003105 | Bladder Cancer Transitional Ce... | filgrastim cisplatin doxorubicin hyd... gemcitabine hyd... ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | NCT01938573 | Recurrent Bladd... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Cisplatin Gemcitabine Hyd... Sirolimus Cystectomy | 18 Years - | University of Washington | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | NCT00313599 | Bladder Cancer Brain and Centr... Breast Cancer Esophageal Canc... Extragonadal Ge... Gastric Cancer Lung Cancer Ovarian Cancer Prostate Cancer | lapatinib paclitaxel | 18 Years - | University of California, San Francisco | |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | NCT00030498 | Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Diffuse A... Adult Ependymob... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Myxopapil... Adult Oligodend... Adult Pilocytic... Adult Primary H... Adult Subependy... Advanced Adult ... Advanced Malign... Male Breast Can... Recurrent Adeno... Recurrent Adult... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Malig... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage II Esopha... Stage II Pancre... Stage III Esoph... Stage III Pancr... Stage IIIB Non-... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Bladde... Stage IV Breast... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Unspecified Adu... Untreated Metas... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | NCT00002949 | Bladder Cancer Cervical Cancer Endometrial Can... Vaginal Cancer | paclitaxel vinorelbine tar... radiation thera... | 18 Years - | University of Chicago |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
